PARPi agents have been approved to treat ovarian cancer patients with and without BRCA1/2 mutations and/or other HR deficiencies, and combined treatment with the PARPi olaparib and the VEGFA-selective blocker bevacizumab is FDA-approved for ovarian cancer as maintenance therapy (Le Saux et al, 2021; O’Malley et al, 2023). Here, VEGFA is linked to ovarian cancer.